M&A Deal Summary

Alfasigma Acquires Sofar

On August 2, 2022, Alfasigma acquired life science company Sofar

Acquisition Highlights
  • This is Alfasigma’s 1st transaction in the Life Science sector.
  • This is Alfasigma’s 1st transaction in Italy.

M&A Deal Summary
Date 2022-08-02
Target Sofar
Sector Life Science
Buyer(s) Alfasigma
Deal Type Add-on Acquisition

Target

Sofar

Trezzano Rosa, Italy
Sofar is an Italian pharmaceutical company active in the research, production, and marketing of drugs, medical devices, and dietary supplements -with a long-standing tradition and well-known to professionals and patients. Sofar was formed in 1968 and is based in Trezzano Rosa, Italy.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Alfasigma

Bologna, Italy
Category Company
Sector Life Science
Revenue 1.0B EUR (2021)
DESCRIPTION

Alfasigma is a multinational pharmaceutical company with 3 production plants in Italy and 2 abroad, and on-site presence in 17 markets plus an indirect presence in about 70 countries. Alfasigma is based in Bologna, Italy.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
Country (Italy) 1 of 1
Year (2022) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-09-26 Intercept

Morristown, New Jersey, United States

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). Intercept is based in Morristown, New Jersey

Buy -
Mergr

Product

Company

Legal